LQDA
Liquidia
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
LQDA Profile
Liquidia Corporation
A biopharmaceutical company focused on the treatment of pulmonary hypertension (PH)
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
--
Liquidia Corporation was incorporated in Delaware on June 17, 2020. The company is a biopharmaceutical company focused on the development, manufacturing and commercialization of products that address unmet patient needs, with a current focus on the treatment of pulmonary hypertension. The company operates as a single entity through two wholly-owned subsidiaries, Liquidia Technologies and Liquidia PAH. The company conducts research, development and manufacture of new products by applying its expertise in cardiopulmonary disease and proprietary PRINT technology, a particle engineering platform capable of accurately producing uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through product development and research with third parties, the company has experience in applying PRINT to a variety of drug delivery routes and drug payloads, including inhalation therapies, vaccines, biological agents, nucleic acids and ophthalmic implants.